Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.38

-9.0%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (10467)	2/17/2004 8:21:48 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) of 52153

Peter, I'll see your $6B and raise you $6B. Lipitor sales in the US are about $7B (last I heard). Generic Mevacor (lovastatin) could replace Lipitor and save $6B. Even better, Mevacor has superior outcomes data though Lipitor has a greater influence on the surrogate marker LDL. There are even cheap versions of Mevacor that are extended release Alticor (ADRX) and a version of Mevacor that includes an extended release niacin Advicor (KOSP). Either of these could replace Lipitor AND offer superior outcomes for the patients while cutting health care costs. Saving billions in health care costs will present some side effects: Congress will spend the savings and more on important government programs for us; the corporations deprived of the revenues can cut back on R&D and we will be spared future expensive drugs that might have been developed with the revenues. <g> ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next